What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The Phase 3 ORIENT-11 trial showed significant improvement in PFS (8.9 vs 5.0 months, HR=0.482) and ORR (51.9% vs 29.8%) with sintilimab compared to chemotherapy. OS benefit was also observed (HR=0.60), but the median OS was not reached. However, the lack of head-to-head trials with other PD-(L)1 inhibitors and reliance on PFS as the primary endpoint limit the evidence strength.
Does the economic case hold at the expected price? — Cost effectiveness
The only cost-effectiveness study available is from China, with no analyses for US/EU/Japan. The ICER was reported in a Chinese model, but no economic evaluations outside China are available, making this domain not assessable.
Is there quality-of-life evidence payers weigh? — Quality of life
No HRQoL or utility data specific to sintilimab in non-squamous NSCLC were reported. ORIENT-11 did not include patient-reported outcomes or utilities, making this domain not assessable.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of sintilimab was consistent with known PD-1 inhibitor toxicities, with no new adverse signals. Grade ≥3 AEs were similar between sintilimab and chemotherapy arms, and no significant increase in treatment-related mortality was observed.
Was the drug compared against what payers expect? — Comparator Selection
The comparator in ORIENT-11 was chemotherapy alone, which is outdated for Western practice where immuno-oncology combinations are standard. This limits the applicability of results to US/EU settings.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was exclusively Chinese, and no patients ≥75 or with ECOG 2 were included. This limits generalizability to Western populations. Subgroup analyses were limited, with no formal analysis by age or smoking status.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Sintilimab would fit into the first-line treatment pathway for non-squamous NSCLC, similar to other PD-1 inhibitors. Standard ICI monitoring and administration protocols are applicable, with no novel care processes anticipated.
Are the wider system costs understood? — Resource Use and Cost Implications
No direct resource-use study of sintilimab was found. All statements regarding resource use are extrapolations, and without actual price points and healthcare utilization data, this domain is not assessable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes large Phase 3 RCTs with strong internal validity. However, the external validity is limited due to the single-country (China) data, and the comparator choice may inflate relative efficacy.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is high uncertainty due to the lack of global trials and reliance on a single-country dataset. The absence of formal sensitivity analyses for Western settings contributes to the uncertainty.
